ID: ALA4877719

Max Phase: Preclinical

Molecular Formula: C24H26F3NO3

Molecular Weight: 433.47

Molecule Type: Unknown

Representations

Canonical SMILES:  COc1cc2c(cc1OC)C(=O)C(CC1(F)CCN(Cc3ccc(F)cc3F)CC1)C2

Standard InChI:  InChI=1S/C24H26F3NO3/c1-30-21-10-16-9-17(23(29)19(16)12-22(21)31-2)13-24(27)5-7-28(8-6-24)14-15-3-4-18(25)11-20(15)26/h3-4,10-12,17H,5-9,13-14H2,1-2H3

Standard InChI Key:  XXNLETSGRFDIFL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 433.47

Molecular Weight (Monoisotopic): 433.1865

AlogP: 4.73

#Rotatable Bonds: 6

Polar Surface Area: 38.77

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.55

CX LogP: 3.92

CX LogD: 3.87

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.66

Np Likeness Score: -0.40

References

1. Zhou Y, Fu Y, Yin W, Li J, Wang W, Bai F, Xu S, Gong Q, Peng T, Hong Y, Zhang D, Zhang D, Liu Q, Xu Y, Xu HE, Zhang H, Jiang H, Liu H..  (2021)  Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,  64  (4.0): [PMID:33570950] [10.1021/acs.jmedchem.0c01863]

Source

Source(1):

• Scientific Literature